Vapreotide

Vapreotide is a synthetic cyclic octapeptide somatostatin analog developed for treatment of acute esophageal variceal bleeding and control of symptoms from hormone-secreting tumors. Its structure incorporates two D-amino acids and a disulfide-bridged cyclic core that maintains the bioactive conformation while providing enhanced metabolic stability.

The compound activates somatostatin receptors (primarily SSTR2 and SSTR5) to suppress growth hormone, glucagon, insulin, and various gastrointestinal hormones. In the vascular system, somatostatin receptor activation reduces splanchnic blood flow and portal pressure, providing the basis for variceal bleeding applications.

Vapreotide was developed as an alternative to octreotide for acute indications, with some studies suggesting advantages in specific clinical scenarios. Its receptor binding profile differs somewhat from octreotide, potentially offering distinct pharmacological properties in certain applications.

Research applications include investigation of somatostatin receptor subtype contributions to various effects, studies of splanchnic hemodynamics in portal hypertension, and exploration of somatostatin analog utility in hormone-secreting tumors and other conditions involving excessive hormone release.